A new study has revealed an important clue as to why immunotherapy fails in many patients with cancer. The study, led by researchers from the University of Birmingham supported by the National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre and the University of… Read More
The first patient has been dosed in a Phase IIa clinical trial testing the drug HTL0039732 to treat advanced solid tumours, Cancer Research UK and Nxera Pharma have announced. The patient was dosed with HTL0039732, a novel EP4 antagonist, in a Phase IIa clinical trial. This… Read More
CAR-T therapy could be an effective treatment for leukaemia, preclinical data published by biotechnology company Gyala Therapeutics suggests. The data emerged from a study highlighting the use of CAR-T therapy, GYA01, to treat acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). The study is the… Read More
BioNTech and Bristol Myers Squibb have revealed global interim Phase II data for their PD-L1xVEGF-A bispecific antibody pumitamig in patients with extensive-stage small cell lung cancer (ES-SCLC) which shows encouraging antitumour activity. The data for pumitamig plus chemotherapy showed a 76.3% confirmed objective response rate (cORR), 100%… Read More
Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies. The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later… Read More
DDW Editor Reece Armstrong speaks to Dr Laura Aguilar, CMO of Diakonos Oncology, about the challenges of treating glioblastoma (GBM) and the approaches the company is taking to help tackle this devastating disease. RA: Why has GBM remained such a hard cancer to treat? LA: First, GBM, also known as… Read More
Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours. The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More
Genomic and spatial technologies are helping to bring greater insights into cancer and diseases such as long Covid, writes Jack DiGiovanna, Chief Science Officer at Velsera. Emerging genomic and spatial technologies are transforming research on complex diseases like cancer and long Covid. These advancements offer unprecedented precision in diagnostics and… Read More
Two studies have uncovered how combining a reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies. Researchers at The Institute of Cancer Research, London, have shown that this combination involving virotherapy can… Read More
A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink. CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells. … Read More
Scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer. The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year. The research was… Read More
Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities. Kumquat received US Food… Read More
In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL). QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone… Read More
A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy. Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer. The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More
A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery. The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More
